Accessibility Menu
Collegium Pharmaceutical logo

Collegium Pharmaceutical

(NASDAQ) COLL

Current Price$36.13
Market Cap$1.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)+195%
5 Year+52%
1 Year+14%
1 Month+5%
Collegium Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 36.272026-07-16
Collegium Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.28%USD 35.812026-07-09
1 month+4.68%USD 34.652026-06-16
3 month+5.41%USD 34.412026-04-17
Year to date-21.66%USD 46.302025-12-31
1 year+14.16%USD 31.772025-07-16
3 year+68.7%USD 21.502023-07-17
5 year+51.82%USD 23.892021-07-16
Since inception+195.12%USD 12.292015-05-07

Collegium Pharmaceutical Financials at a Glance

Market Cap

$1.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$796.33M

Net Income (TTM)

$74.95M

EPS (TTM)

$2.04

P/E Ratio

17.76

Dividend

$0.00

Beta (Volatility)

0.59 (Low)

Price

$36.13

Volume

316,576

Open

$36.00

Previous Close

$36.08

Daily Range

$35.50 - $36.93

52-Week Range

$29.19 - $50.79

Estimated Earnings Date

Aug 6, 2026

COLL News

SellAlert-Purple.png

Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD

Seena HassounaMar 30, 2026
SellAlert-Red.png

Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million

Andy GouldMar 25, 2026
SellAlert-Purple.png

Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025

Adé HennisJan 14, 2026
Foolcom-Featured.png

Collegium (COLL) Q2 Revenue Jumps 29%

Motley Fool Markets TeamAug 7, 2025
A woman looking at a set of indexes and graphs

Why Collegium Pharmaceutical Rose Nearly 10% on Tuesday

Eric VolkmanFeb 9, 2021
GettyImages-693870464

Investing $5,000 in These 2 Biotechs Could Make You Rich

Alex CarchidiOct 25, 2020
prescription-drugs-on-cash

3 Top Healthcare Stocks You Can Buy Now for Less Than $40

Cory RenauerOct 4, 2020
GettyImages-1162543608

Here's the Best Healthcare Stock on Robinhood to Buy Now

Zhiyuan SunSep 22, 2020
Page 1

COLL: Motley Fool Moneyball Superscore

62

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Collegium Pharmaceutical

Collegium makes medicines for people dealing with severe pain or ADHD. These products help patients manage discomfort or stay focused during their daily routines. The company aims to make these treatments safer and more effective.

What the Company Sells

  • Pain Management Portfolio: Extended-release and immediate-release opioids like Xtampza ER and Belbuca for severe pain.
  • ADHD Treatment: Jornay PM for patients aged six and older; this stimulant is taken in the evening.
  • Constipation Relief: Symproic tablets used to treat constipation caused by the long-term use of opioid medications.

Growing the Business

  • Acquired Ironshore on September 3, 2024, to enter the neuropsychiatry market.
  • Expanded the product line by completing the BDSI Acquisition, which added two new treatments.
  • Partnered with Hikma Pharmaceuticals USA Inc. to launch generic versions of its tapentadol medications in early 2026.
  • Secured pediatric exclusivity for the Nucynta Products, extending market protection into 2027.

Why the Company Stands Out

The company uses DETERx technology to create wax-based microspheres that make pain pills harder to crush or inject. Collegium maintains two specialized sales teams that reach over 30,000 healthcare professionals across the United States.

The Financial Scorecard

  • Revenue reached $205.4 million in Q4 2025, up 12.9% from $181.9 million in Q4 2024.
  • Operating income hit $59.2 million in Q4 2025, a 55.4% increase year-over-year.
  • Net income grew to $17 million in Q4 2025, up 35.3% from $12.5 million in Q4 2024.
  • Free cash flow reached $122.4 million in Q4 2025, up 45.5% from the previous year.

Bottom Line

Collegium has evolved from a pain-focused firm into a broader specialty pharmaceutical business. Strategic acquisitions and proprietary drug-delivery technologies now support its growth across multiple medical fields.

AI Generated • May 1, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

423

CEO

Vikram Karnani, MBA

Website

www.collegiumpharma.com

Headquarters

Stoughton, MA 02072, US

COLL Financials

Key Financial Metrics (TTM)

Gross Margin

60.68%

Operating Margin

23.85%

Net Income Margin

9.41%

Return on Equity

26.74%

Return on Capital

15.06%

Return on Assets

4.54%

Earnings Yield

5.63%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

32.43M

Volume

316.58K

Avg. Volume

441.85K

Financials (TTM)

Gross Profit

$483.18M

Operating Income

$189.91M

EBITDA

$609.91M

Operating Cash Flow

$331.04M

Capital Expenditure

-$1.21M

Free Cash Flow

$329.83M

Cash & ST Invst.

$421.75M

Total Debt

$808.06M

Collegium Pharmaceutical Performance Analysis

Collegium Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 463,933,00067.6%
20232023-12-31USD 566,767,00022.2%
20242024-12-31USD 631,449,00011.4%
20252025-12-31USD 780,567,00023.6%
Collegium Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-305.8%
Q32025-09-3011.4%
Q42025-12-31-1.9%
Q12026-03-31-5.8%
Collegium Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.74N/A
20232023-12-31USD 1.29N/A
20242024-12-31USD 1.8643.6%
20252025-12-31USD 1.73-6.6%
Collegium Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30362.0%
Q32025-09-30147.1%
Q42025-12-31-45.2%
Q12026-03-31-13.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$193.52M

+8.9%

Gross Profit

$117.25M

+20.5%

Gross Margin

60.59%

N/A

Market Cap

$1.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.78M

N/A

Employees

423

N/A

Net Income

$14.50M

+499.8%

EBITDA

$90.54M

+12.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$421.75M

+113.2%

Total Debt

$808.06M

-4.3%

Accounts Receivable

$228.76M

+0.0%

Inventory

$42.74M

+14.8%

Long Term Debt

$777.77M

-0.1%

Short Term Debt

$34.07M

-48.3%

Return on Assets

4.54%

N/A

Return on Invested Capital

15.61%

N/A

Free Cash Flow

$56.84M

+4.1%

Operating Cash Flow

$57.11M

+3.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GDRXGoodRx Holdings, Inc.
$3.14+0.64%
CRONCronos Group Inc.
$2.79+1.45%
NKTRNektar Therapeutics
$68.26+1.80%
PCRXPacira BioSciences, Inc.
$25.61+0.04%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
NFLXNetflix
$68.95-0.07%
PATHUiPath
$12.15+0.01%

Questions About COLL

What is the current price of Collegium Pharmaceutical?

Collegium Pharmaceutical is trading at $36.08 per share.

What is the 52-week range for Collegium Pharmaceutical?

Over the past 52 weeks, Collegium Pharmaceutical has traded between $29.19 and $50.79.

How much debt does Collegium Pharmaceutical have?

As of the most recent reporting period, Collegium Pharmaceutical reported total debt of $929.69M.

How much cash does Collegium Pharmaceutical have on hand?

Collegium Pharmaceutical reported $288.50M in cash and cash equivalents in its most recent financial results.

What is Collegium Pharmaceutical’s dividend yield?

Collegium Pharmaceutical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services